| Apr-19-19 10:43AM | GSK cutting employees at its R&D unit in Collegeville American City Business Journals |
| Apr-18-19 11:29AM | Clovis Focuses on Rubraca Label Expansion, Competition Stiff Zacks |
| Apr-17-19 02:30PM | COPD space about to have another drug this time from a Morrisville concern American City Business Journals |
| 11:01AM | Emergent's (EBS) Chikungunya Vaccine Positive in Phase II Study Zacks |
| Apr-16-19 11:07AM | Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up Zacks |
| 10:57AM | Novartis' (NVS) BLA for Ophthalmology Drug Accepted by FDA Zacks |
| Apr-15-19 09:57AM | Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer Zacks |
| 05:28AM | London's FTSE 100 tugged down by miners; IWG lifts midcaps Reuters |
| Apr-14-19 08:07PM | Top 5 Dividend Stocks in the FTSE for 2018 Investopedia |
| Apr-12-19 11:08AM | Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group Zacks |
| 10:30AM | Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal Zacks |
| Apr-11-19 06:20PM | Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon Zacks |
| Apr-10-19 10:14AM | AstraZeneca/Merck's Lynparza Wins EU Nod for Breast Cancer Zacks |
| Apr-09-19 11:19AM | Dont Give Up on Gilead Stock After GlaxoSmithKline Beat It to a New HIV Drug, Analyst Says Barrons.com |
| 10:59AM | Emergent's (EBS) Strong Vaccine Portfolio to Fuel Growth Zacks |
| 08:02AM | Glaxo's Dovato Gets FDA Nod for Treatment-Naive HIV Patients Zacks |
| Apr-08-19 05:25PM | Gilead Files sNDA for Label Expansion of HIV Therapy Descovy Zacks |
| 04:51PM | GSK wins U.S. nod for two-drug HIV combination Reuters |
| 03:56PM | U.S. FDA approves GSK's two-drug HIV treatment Reuters |
| 03:46PM | U.S. FDA approves GSK's two-drug HIV treatment Reuters |
| 10:00AM | 3 Top Biotech Stocks to Buy in April Motley Fool |
| 04:26AM | GSK two-drug/one-pill HIV treatment given FDA approval in US Financial Times |
| Apr-05-19 08:00AM | Health Day Checkup of Medical ETFs: 5 Top Picks Zacks |
| Apr-04-19 09:39AM | Novartis Resubmits BLA to FDA for Biosimilar of Neulasta Zacks |
| Apr-03-19 10:22AM | Clovis Posts Data on Rubraca Study for Pancreatic Cancer Zacks |
| Apr-02-19 10:18AM | Novartis Gets Approval for Psoriasis Drug Cosentyx in China Zacks |
| 10:04AM | Merck's Keytruda Gets Nod for First-Line Lung Cancer in China Zacks |
| Apr-01-19 02:31PM | Top Analyst Reports for Chevron, IBM & Medtronic Zacks |
| 08:53AM | 3 Big Pharma Stocks to Add to Your Portfolio This April Zacks |
| Mar-29-19 08:10PM | 3 Dividend Stocks That Pay You Better Than Coca-Cola Does Motley Fool |
| 12:45PM | Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates Benzinga |
| 12:10PM | The Brexit Day That Wasn't Leaves Britain Counting the Cost Bloomberg |
| Mar-28-19 01:29PM | European shares give up gains as banks weigh amid concerns on growth, Brexit Reuters |
| 09:52AM | One Key Strategy to Build Your Ultimate Retirement Portfolio InvestorPlace |
| Mar-27-19 02:47PM | 5 Cancer-Fighting Stocks to Boost Portfolio Gains Zacks |
| 09:33AM | Were Hedge Funds Right About Deserting GlaxoSmithKline plc (GSK)? Insider Monkey |
| Mar-26-19 07:45PM | Better Buy: Eli Lilly vs. GlaxoSmithKline Motley Fool |
| Mar-22-19 07:00AM | FOCUS-UPS eyes in-home health services with U.S. vaccine project Reuters |
| 01:00AM | FOCUS-UPS eyes in-home health services with U.S. vaccine project Reuters |
| Mar-20-19 11:24AM | Emergent Begins Phase III Study on Anthrax Vaccine AV7909 Zacks |
| 10:43AM | Glaxo Presents Encouraging Data on Endometrial Cancer Drug Zacks |
| Mar-19-19 03:00PM | Post-GSK purchase, Tesaro readies for cancer clash with Merck American City Business Journals |
| 02:19PM | GSK reports positive data from trial of endometrial cancer drug Reuters |
| Mar-18-19 03:53PM | Novartis' (NVS) Alcon Acquired PowerVision for $285 Million Zacks |
| Mar-15-19 01:37PM | UK shares up after vote for Brexit delay; oil majors gain Reuters |
| Mar-14-19 03:12PM | 5 Undervalued Stocks to Invest In InvestorPlace |
| Mar-12-19 05:45PM | GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know Zacks |
| 09:14AM | Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now? Zacks |
| 07:31AM | How the UK Makes Money Investopedia |
| Mar-08-19 03:46PM | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks |
| 01:24PM | Top Research Reports for Microsoft, Mastercard & General Electric Zacks |
| Mar-07-19 02:45PM | Why the Triangle is ranked among the top 5 life science hubs in the U.S. American City Business Journals |
| 01:50PM | Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy Zacks |
| 01:45AM | [$$] Monthly jab for HIV treatment passes late-stage trials Financial Times |
| Mar-06-19 02:55PM | Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA Zacks |
| Mar-05-19 08:42AM | Merck Gets CHMP Nod for Six-Week Dosing Option of Keytruda Zacks |
| Mar-04-19 08:15AM | New Research: Key Drivers of Growth for GlaxoSmithKline plc, nVent Electric, Dana, FMC, Qualys, and Affiliated Managers Group Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| Mar-01-19 02:37PM | 3 Life Sciences Stocks to Invest In InvestorPlace |
| Feb-27-19 03:30PM | Mallinckrodt (MNK) Rallies as Earnings Beat Estimates in Q4 Zacks |
| 12:48PM | Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates Zacks |
| 12:40PM | Versum Sticks With Merger Plan as German Merck Barges In Bloomberg |
| 11:49AM | Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down Zacks |
| 10:47AM | Bayer (BAYRY) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks |
| 10:14AM | Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q4 Zacks |
| 09:38AM | Top Ranked Income Stocks to Buy for February 27th Zacks |
| 08:12AM | Clovis (CLVS) Q4 Earnings Lag Estimates, Rubraca Sales Recover Zacks |
| 08:06AM | MarketPulse: Mylan Bleeds After Q4 Results, Guidance Fall Short Investing.com |
| 07:15AM | AstraZeneca/Merck's Lynparza Meets Endpoint in POLO Study Zacks |
| Feb-26-19 10:47AM | Sanofi/Regeneron Disagree With Jury Verdict in Amgen's Favor Zacks |
| 10:29AM | Top Ranked Income Stocks to Buy for February 26th Zacks |
| 09:39AM | The Zacks Analyst Blog Highlights: Boeing, GlaxoSmithKline and Rio Tinto Zacks |
| 07:16AM | Better Buy: GlaxoSmithKline vs. Eli Lilly Motley Fool |
| Feb-25-19 10:27AM | Novartis In-Licenses Rights to Heart Candidate From Ionis Zacks |
| 07:00AM | [$$] SFO appoints Sarah Lawson QC as new general counsel Financial Times |
| Feb-22-19 04:58PM | [$$] U.K. Closes Corruption Probes of GlaxoSmithKline, Rolls-Royce Individuals The Wall Street Journal |
| 12:18PM | British fraud office abandons Rolls-Royce, GSK investigations Reuters |
| 11:48AM | British fraud office abandons Rolls-Royce, GSK investigations Reuters |
| 11:26AM | Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates Zacks |
| 08:52AM | Top Ranked Income Stocks to Buy for February 22nd Zacks |
| 07:27AM | UK's Serious Fraud Office drops probes at Rolls Royce, GSK Reuters |
| 06:34AM | [$$] SFO ends investigations into Rolls-Royce and GSK Financial Times |
| 05:00AM | [$$] SFO abandons cases as new chief tackles backlog Financial Times |
| Feb-21-19 03:34PM | Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y Zacks |
| 10:08AM | Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks |
| 09:12AM | Merck Gets Priority Review for Keytruda in Third-Line SCLC Zacks |
| Feb-20-19 09:53AM | Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct Zacks |
| Feb-19-19 04:14PM | [$$] Drug Maker Pernix Therapeutics Files for Bankruptcy, Blaming Competition From Generics The Wall Street Journal |
| 09:14AM | Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo Zacks |
| 09:04AM | New Strong Buy Stocks for February 19th Zacks |
| Feb-15-19 04:27PM | Innoviva, Inc. -- Moody's announces completion of a periodic review of ratings of Innoviva, Inc. Moody's |
| 09:02AM | Top Ranked Growth Stocks to Buy for February 15th Zacks |
| Feb-14-19 03:44PM | Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B Zacks |
| 02:02PM | Zoetis (ZTS) Beats on Q4 Earnings & Sales, Shares Up Zacks |
| 08:58AM | AstraZeneca's (AZN) Q4 Earnings Beat, New Drugs Drive Sales Zacks |
| 08:14AM | Top Ranked Income Stocks to Buy for February 14th Zacks |
| 07:13AM | New Strong Buy Stocks for February 14th Zacks |
| Feb-13-19 03:29AM | Edited Transcript of GSK.L earnings conference call or presentation 6-Feb-19 2:00pm GMT Thomson Reuters StreetEvents |
| Feb-12-19 11:01AM | Mylan launches Advair generic at one-third price Reuters |
| 10:41AM | Mylan launches Advair generic at one-third price Reuters |
| 09:12AM | Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer Zacks |
|
|
|
| GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories primarily under the Sensodyne, parodontax, Poligrip, Voltaren, Panadol, Otrivin, and Theraflu brand names. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, pods, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, and malted drinks and foods. Its primary collaboration is with 23andMe; and strategic alliance is with Merck KGaA to jointly develop and commercialize M7824. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| GLAXOSMITHKLINE PLC | Former 10% holder | Jul 30 | Buy | 11.00 | 148,818 | 1,636,998 | 624,422 | Aug 01 06:32 PM | | GLAXOSMITHKLINE PLC | 10% Owner | Jul 17 | Buy | 12.50 | 80,000 | 1,000,000 | 1,934,006 | Jul 17 05:01 PM | | GLAXOSMITHKLINE PLC | 10% Owner | Jul 02 | Buy | 13.00 | 269,230 | 3,499,990 | 3,697,912 | Jul 03 05:59 PM |
|
